Marshall Wace, LLP Medicinova Inc Transaction History

Marshall Wace, LLP

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 May 16, 2022	SELL	$2.19 - $2.81 $241,338 - $309,662	-110,200 Closed	0 $0
Q4 2021 Feb 14, 2022	SELL	$2.61 - $4.42 $455,450 - $771,298	-174,502 Reduced 61.29%	110,200 $295,000
Q3 2021 Nov 15, 2021	SELL	$3.4 - $4.24 $640,063 - $798,196	-188,254 Reduced 39.8%	284,702 $1.08 Million
Q2 2021 Aug 13, 2021	BUY	$3.76 - $5.14 $1.78 Million - $2.43 Million	472,956 New	472,956 $2.01 Million
Q2 2020 Aug 13, 2020	SELL	$3.06 - $7.06 $39,008 - $90,000	-12,748 Closed	0 $0
Q1 2020 May 15, 2020	SELL	$2.9 - $6.97 $24,197 - $58,157	-8,344 Reduced 39.56%	12,748 $47,000
Q4 2019 Feb 14, 2020	BUY	$6.48 - $8.76 $136,676 - $184,765	21,092 New	21,092 $142,000
Q2 2019 Aug 14, 2019	SELL	$8.29 - $13.22 $54,100 - $86,273	-6,526 Closed	0 $0
Q1 2019 May 14, 2019	BUY	$6.82 - $10.27 $44,507 - $67,022	6,526 New	6,526 $54,000

4.83M

9.4K

Ticker MNOV
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 49,046,200
Market Cap $106M
Description
MediciNova, Inc., a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. The company is developing MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent for treating neurological disorders, such as primary and ...

Get notified when there are updates to the investment portfolio of Marshall Wace, LLP, based on Form 13F filings with the SEC.

Stay updated on Marshall Wace, LLP with notifications on news.